Immunocore Advances Half-Life Extended Cancer Treatment With First Patient Dosed
Immunocore Advances Half-Life Extended Cancer Treatment With First Patient Dosed
Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announces that the first patient has been dosed in the Phase 1 trial of IMC-P115C (PRAME-HLE-A02), which is a half-life extended ImmTAC candidate.
Immunocore Holdings plc（纳斯达克：IMCR）（"Immunocore"或"公司"）是一家商业阶段的生物技术公司，开创并提供变革性的免疫调节药物，以显著改善癌症、传染病和自身免疫疾病患者的治疗效果。今天宣布，第一位患者已在IMC-P115C（PRAME-HLE-A02）一期临床试验中接受了用药，该药物为半衰期延长的ImmTAC候选药物。
IMC-P115C was developed to improve patient convenience by reducing the frequency of treatment administration. It is Immunocore's first half-life extended candidate, and sixth ImmTAC candidate to enter the clinic. IMC-P115C is a PRAME x CD3 ImmTAC bispecific protein, with the same CD3 and targeting the same HLA-A*02:01 PRAME (PReferentially expressed Antigen in MElanoma) peptide as brenetafusp.
IMC-P115C的开发旨在通过减少治疗给药的频率来提高患者的便利性。它是Immunocore的第一个半衰期延长的候选药物，也是第六个进入临床的ImmTAC候选药物。IMC-P115C是一种PRAME x CD3的ImmTAC双特异性蛋白，具有相同的CD3并针对与brenetafusp相同的HLA-A*02:01 PRAME（优先表达的黑色素瘤抗原）肽。
